Gastrointestinal Amyloidosis

Gastrointestinal amyloidosis (GIA) is a rare but clinically significant disease characterized by the extracellular deposition of amyloid fibrils, proteins adopting a distinctive β-pleated sheet conformation, within the gastrointestinal tract, disrupting normal organ function ^[3]B3b. The diagnosis hinges on histopathological confirmation: Congo Red staining reveals apple-green birefringence under polarized light, the diagnostic gold standard ^[3]B3b.

Classification by Amyloid Type

GIA is classified by the precursor protein, a distinction that dictates prognosis and therapy. Twelve amyloid types have been identified in GI specimens, but three dominate clinical practice ^[9]D5:

Additional rare types, AH, AApoAIV, AEFEMP1, ALys, AApoAI, ALECT2, Aβ2M, AGel, AFib, collectively account for <4% of cases ^[9]D5.

Systemic vs. Localized Disease

GIA occurs in two distinct patterns. Systemic amyloidosis involves multi-organ deposition; GI involvement is often an unexpected finding that signals systemic disease ^[9]D5. Localized GI amyloidosis is confined to the gastrointestinal tract, most commonly the stomach (42% of localized cases), and carries an excellent prognosis with curative resection alone (100% cure rate in reported series) ^[1]B2a.

Clinical Significance

GIA remains relatively rare, with an estimated prevalence of approximately 5% among all amyloidosis patients and a detection rate as low as 0.01% in unselected endoscopic cohorts ^[3]B3b. Yet it is a critical diagnosis: most AL and ATTR patients with GI amyloid are ultimately found to have cardiac involvement (83.5% of AL; 100% of ATTR), and the condition therefore serves as an early marker of systemic disease with major therapeutic implications ^[9]D5.

Pearl: GI amyloidosis is most often an unexpected finding on biopsy, but because over 80% of AL cases and 100% of ATTR cases with GI involvement have concurrent cardiac amyloid, any positive Congo Red stain on a GI biopsy should trigger an immediate cardiology evaluation and amyloid typing by proteomics or immunohistochemistry ^[9]D5.

The classification of amyloidosis by precursor protein dictates not only prognosis but also the pattern of gastrointestinal involvement, as the physicochemical properties of each amyloid type influence tissue tropism and the sequence of organ damage. The unifying pathogenic event is the extracellular deposition of abnormally folded, insoluble protein fibrils that adopt a β-pleated sheet conformation, disrupting normal tissue architecture and function ^[8]D5. In the gastrointestinal tract, this deposition follows a stereotyped, progressive sequence that explains the spectrum of clinical manifestations.

Sequential Tissue Involvement

Amyloid deposition in the gut is not random; it proceeds in a stepwise fashion. Deposition begins in the vasculature, amyloid fibrils are consistently found in the walls of submucosal vessels in all amyloidosis patients, regardless of type ^[11]D5. From this vascular nidus, the process extends to the mucosal and submucosal compartments, then to the muscular layers, and ultimately to the interstitial cells of Cajal (ICC) and the myenteric plexus ^[11]D5. In a systematic autopsy study, amyloid was present in the vascular walls of all patients, in the mucosa of 67% of AA cases, and in the muscular layers of 64% of all amyloidosis patients, most prominently in AA ^[11]D5. Amyloid deposits surrounding the myenteric plexus were associated with loss of the ICC network, though neuronal density remained preserved ^[11]D5. This sequential model explains why early disease may be asymptomatic or cause only subtle vascular compromise, whereas advanced involvement produces severe dysmotility, malabsorption, and bleeding.

Type-Specific Deposition Patterns

The depth and distribution of amyloid within the gastrointestinal wall vary by precursor protein. In a large proteomics-based series of 2511 gastrointestinal amyloid specimens, AL (immunoglobulin light chain) amyloidosis accounted for 77.9% of cases, followed by ATTR (transthyretin) at 11.3% and AA (serum amyloid A) at 6.6% ^[9]D5. All three types commonly involved submucosal vessels, but they showed characteristic differences in more superficial compartments: AA amyloid preferentially deposits in the mucosal layer, whereas AL and ATTR tend to accumulate in the submucosa ^[3]B3b[9]D5. This tropism has diagnostic implications, mucosal biopsies are more likely to capture AA deposits, while deeper sampling (including submucosa) is needed for AL and ATTR. In the stomach, the lamina propria and muscularis mucosa are predominantly affected; in the duodenum and colorectum, the submucosa is significantly more involved ^[3]B3b.

Triggers and Precursor Overproduction

The type of amyloidosis reflects the underlying disease process:

• AL amyloidosis arises from a clonal plasma cell dyscrasia that produces excessive immunoglobulin light chains, which misfold and aggregate ^[9]D5. Gastrointestinal involvement often signals systemic disease, 83.5% of AL patients in one series had concurrent cardiac amyloidosis ^[9]D5.
• AA amyloidosis is driven by chronic inflammation, which stimulates hepatic overproduction of serum amyloid A (SAA) protein. In a mouse model of persistent dermatitis, overproduced SAA in the liver led to amyloid deposition in the stomach, small intestine, and large intestine, causing hypoalbuminemia ^[10]D5. Clinically, AA amyloidosis complicates chronic infections (e.g., bronchiectasis, tuberculosis), autoimmune diseases (e.g., rheumatoid arthritis, familial Mediterranean fever), and, rarely, solid tumors such as proliferating pilomatricoma ^[4]C4[6]C4. Even recurrent SARS-CoV-2 infection has been reported to trigger GI AA amyloidosis via SAA overproduction ^[13]C4.
• ATTR amyloidosis results from deposition of wild-type or mutant transthyretin; amino acid abnormalities indicative of amyloidogenic mutations were detected in 24.4% of ATTR cases in one series ^[9]D5. ATTR commonly involves the submucosa and is frequently associated with cardiac involvement (100% in that series) ^[9]D5.

Clinical Consequences of the Cascade

The sequential deposition explains the clinical phenotype. Early vascular involvement may cause mucosal ischemia and occult bleeding. Mucosal and submucosal deposits produce friability, erosions, and ulcerations, leading to hematochezia or melena. Muscular layer infiltration disrupts peristalsis, causing dysmotility, abdominal pain, and pseudo-obstruction. Loss of ICC and myenteric plexus involvement heralds severe, refractory dysmotility ^[11]D5. Malabsorption and protein-losing enteropathy result from extensive mucosal and submucosal deposition, while amyloid infiltration of the liver can cause hepatomegaly and portal hypertension ^[2]D5.

Mechanism Flowchart

Pearl: The sequential progression from vascular to muscular to neural involvement means that early GI amyloidosis may be asymptomatic or present only with occult bleeding; once dysmotility or malabsorption develops, deeper tissue layers are already compromised, and the disease is likely advanced.

The deposition patterns described above arise from a heterogeneous set of underlying conditions, and the epidemiological profile of gastrointestinal amyloidosis reflects this diversity. No precise incidence for GI involvement alone has been reported, but the estimated incidence of systemic AL amyloidosis, the most common type affecting the GI tract, is 6-10 cases per 100,000 individuals annually in Western Europe and the United States ^[4]C4.

Demographics

The median age at diagnosis is 64.4 years (systematic review) to 61.7 years (retrospective cohort), with a consistent male predominance (63% and 61.1%, respectively) ^[1]B2a[3]B3b. AL amyloidosis shows a male-to-female ratio of approximately 3:2 ^[4]C4.

Amyloid Type Distribution

In the largest proteomics-based series of 2511 GI amyloid specimens, the distribution was: AL 77.9%, ATTR 11.3%, AA 6.6%, and rarer types including AH, AApoAIV, AEFEMP1, ALys, AApoAI, ALECT2, Aβ2M, AGel, and AFib ^[9]D5. Among ATTR cases, 24.4% harbored amyloidogenic mutations ^[9]D5. AL and ATTR patients were ultimately found to have cardiac involvement in 83.5% and 100% of cases, respectively ^[9]D5.

Risk Factors

• AL amyloidosis: Underlying plasma cell dyscrasia, including multiple myeloma ^[14]C4[15]C4.
• AA amyloidosis: Chronic inflammatory conditions (rheumatoid arthritis, familial Mediterranean fever, chronic infections), common variable immunodeficiency (CVID) ^[4]C4[6]C4. In CVID, AA amyloidosis most frequently involves kidneys (n=11/17) and GI tract (n=5/17) ^[4]C4.
• ATTR amyloidosis: Wild-type or hereditary transthyretin mutations ^[9]D5.
• Localized GI amyloidosis: Often AL type, occurs without systemic disease; may remain stable over years ^[12]C4.
• Infection-associated: SARS-CoV-2 infection reported as a trigger for GI AA amyloidosis, presenting within weeks ^[13]C4.
• Tumor-associated: Solid tumors such as proliferating pilomatricoma can harbor AA amyloid deposits; resection may lead to remission of GI amyloidosis ^[6]C4.

Special Considerations

Post-infection timing: GI AA amyloidosis has been reported 4 weeks after SARS-CoV-2 infection in an immunocompromised patient ^[13]C4. Tumor-associated AA amyloidosis may resolve after complete resection of the inciting tumor, as seen with proliferating pilomatricoma ^[6]C4.

Pearl: When evaluating a patient with unexplained GI symptoms and a history of chronic inflammation, plasma cell dyscrasia, or recurrent infections, consider GI amyloidosis; the high rate of cardiac involvement in AL (83.5%) and ATTR (100%) warrants prompt systemic evaluation, even if GI symptoms are the presenting complaint ^[9]D5.

From the epidemiological perspective, the clinical challenge lies in the non-specific nature of gastrointestinal amyloidosis symptoms, which often delay recognition until systemic involvement is advanced. The presentation spans a spectrum from asymptomatic incidental findings to life-threatening bleeding or perforation, and the pattern of symptoms reflects both the amyloid type and the anatomic site of deposition.

Presenting Symptoms

• Abdominal pain is the most common symptom, reported in 41% of patients with localized disease ^[1]B2a. The pain is often vague, episodic, and misattributed to irritable bowel syndrome or gastritis.
• Dysmotility manifests as diarrhea, constipation, early satiety, nausea, and vomiting. Amyloid infiltration of the muscularis propria disrupts peristalsis, leading to pseudo-obstruction in severe cases ^[2]D5.
• Gastrointestinal bleeding occurs in a substantial minority, presenting as hematochezia, melena, or iron-deficiency anemia. Progressive microcytic anemia may be the sole indication for endoscopy ^[16]C4.
• Malabsorption and weight loss result from mucosal and submucosal deposition, causing steatorrhea, vitamin deficiencies, and unintentional weight loss ^[2]D5.
• Systemic clues include orthostatic dizziness (autonomic dysfunction), peripheral edema (nephrotic syndrome from renal amyloid), and fatigue (anemia or cardiac involvement) ^[2]D5.

Patients may also be asymptomatic, with amyloid discovered incidentally during endoscopy performed for other indications ^[1]B2a.

Physical Examination Findings

• Hepatomegaly is common, and splenomegaly or ascites may indicate portal hypertension from hepatic amyloid deposition ^[2]D5.
• Macroglossia is a classic but infrequent sign of AL amyloidosis, often accompanied by dental indentations and dysphagia.
• Orthostatic hypotension (a drop in systolic blood pressure ≥20 mm Hg upon standing) signals autonomic neuropathy , a poor prognostic marker.
• Pallor reflects chronic anemia; peripheral edema suggests renal involvement.

Phenotypic Variants

Red Flags and Atypical Presentations

• Unexplained GI bleeding in a patient >30 years with proteinuria, autonomic symptoms, or hepatomegaly should prompt consideration of amyloidosis ^[2]D5.
• Gastric mass mimicking cancer: a mucosal bulge with surface erosion may be mistaken for gastric carcinoma, but biopsy shows chronic inflammation; Congo red staining is essential ^[15]C4.
• Isolated small bowel polyposis: filiform polyps up to 3 cm in the duodenum and jejunum can be the only manifestation, discovered during workup for anemia ^[16]C4.
• Diffuse bowel wall thickening on PET/CT with intense FDG uptake may be the first clue in multiple myeloma patients presenting with abdominal pain and hematochezia ^[14]C4.
• Persistent gastric erythema unresponsive to acid suppression or H. pylori therapy should raise suspicion, especially when accompanied by systemic signs ^[5]C4.

Pearl: In any patient over 30 with unexplained chronic diarrhea, weight loss, autonomic dysfunction, or proteinuria, gastrointestinal amyloidosis should be considered, even if endoscopy appears normal or shows only subtle erythema ^[2]D5.

The diagnosis of gastrointestinal amyloidosis hinges on histopathologic confirmation, as clinical and endoscopic features are nonspecific and overlap with more common conditions. The gold-standard diagnostic test is endoscopic biopsy with Congo red staining, which demonstrates apple-green birefringence under polarized light ^[15]C4. Because amyloid deposition often involves the submucosa, deep tissue sampling is critical to avoid false-negative results ^[3]B3b.

Endoscopic Findings and Classification

Endoscopic appearances are diverse and cannot reliably predict amyloid type ^[18]C4. A proposed classification from a review of 127 patients identifies five distinct lesion types ^[7]D5:

In a separate series of 36 patients, elevated lesions were most common in the esophagus, stomach, and small intestine (57.1%), while white patches were prevalent in the duodenum (66.7%) ^[3]B3b. Rarely, amyloidosis can present as isolated small bowel polyposis, including filiform polyps up to 3 cm ^[16]C4.

Biopsy and Histology

Biopsy with Congo red staining is the gold standard. The detection rate varies by site: the small intestine has the highest yield (100%), followed by the stomach (62.8%), while the colorectum has the lowest (37.5%) ^[3]B3b. Amyloid deposition most frequently involves the muscularis mucosae regardless of type; lamina propria involvement is less common in ATTR than in other types ^[18]C4. In 22% of patients, the first diagnosis of amyloidosis is made on gastric biopsy ^[18]C4.

Amyloid typing is essential to guide treatment and prognosis. Laser microdissection/mass spectrometry is the preferred method, as immunohistochemistry can be unreliable ^[18]C4. In a series of 79 gastric amyloidosis cases, typing revealed AL (67%), ATTR (18%), AA (9%), and apolipoprotein A1 (3%) ^[18]C4. For localized gastrointestinal amyloidosis, all typed cases were lambda light chain ^[17]B2b.

Laboratory Studies

Laboratory evaluation supports the diagnosis and typing but is not diagnostic alone. Serum and urine immunofixation electrophoresis, serum free light chain assay, and bone marrow biopsy are used to identify an underlying plasma cell dyscrasia in AL amyloidosis ^[17]B2b. However, in localized disease, these tests may be normal ^[16]C4. For suspected hereditary amyloidosis, genetic testing for transthyretin (TTR) mutations is indicated.

Imaging

Cross-sectional imaging (CT, MRI) may show nonspecific findings such as bowel wall thickening, luminal dilation, or mesenteric infiltration, but these are neither sensitive nor specific. Endoscopy remains the primary diagnostic modality.

Diagnostic Algorithm

Step 1: Perform upper endoscopy and colonoscopy with deep biopsies (including submucosa) from any abnormal-appearing mucosa and from normal-appearing duodenum. Step 2: If Congo red staining is negative but clinical suspicion remains high, proceed to push enteroscopy or capsule endoscopy to sample the small intestine, which has the highest yield ^[3]B3b. Step 3: Once amyloid is confirmed, type the amyloid using laser microdissection/mass spectrometry ^[18]C4. Step 4: Determine whether disease is systemic or localized by evaluating for plasma cell dyscrasia (serum free light chains, immunofixation, bone marrow biopsy) and other organ involvement (echocardiography for cardiac amyloid, renal biopsy if proteinuria).

Pearl: Deep biopsy including submucosa is critical; the small intestine has the highest diagnostic yield, so consider push enteroscopy or capsule endoscopy if suspicion remains high despite negative upper/lower endoscopy.

Once the diagnosis of gastrointestinal amyloidosis (GIA) is confirmed, risk stratification hinges on the endoscopic appearance, amyloid type, and extent of systemic involvement, as these factors predict prognosis and guide management intensity.

Endoscopic Classification and Prognosis

Song et al. proposed a five-type endoscopic classification based on 127 GIA patients: protruding (23.6%), hemorrhagic (25.2%), ulcerative (22.0%), granular (15.7%), and nonspecific (13.4%) ^[7]D5. The protruding type is significantly associated with localized amyloidosis (71.4% of protruding lesions), whereas the hemorrhagic type predominates in AL amyloidosis (42.6%) and the ulcerative type in AA amyloidosis (47.1%) (p<0.001) ^[7]D5. The granular type correlates with dysmotility symptoms (p=0.018) ^[7]D5. Prognostically, the protruding type carries a favorable outcome: only 2 of 30 patients died, compared with 36.1% mortality among the other types combined over a median follow-up of 95.5 months (p=0.007) ^[7]D5. This classification provides a practical tool for initial risk stratification.

Amyloid Type and Systemic Risk

Amyloid typing is essential for risk stratification because the type dictates the likelihood of systemic involvement. In a large proteomics-based series of 2511 GI amyloid specimens, AL was the most common type (77.9%), followed by ATTR (11.3%) and AA (6.6%) ^[9]D5. Importantly, most AL and ATTR patients had cardiac involvement (83.5% of AL; 100% of ATTR) ^[9]D5. Thus, a diagnosis of AL or ATTR GI amyloidosis should prompt urgent cardiac evaluation, as cardiac involvement is the major determinant of prognosis. AA amyloidosis, while less common, is often associated with chronic inflammatory conditions and may present with ulcerative lesions ^[7]D5.

Histologic Staging of Dysmotility

Den Braber-Ymker et al. proposed a sequential histologic model for intestinal dysmotility in amyloidosis: amyloid deposition begins in the vasculature, then involves the muscular layers, followed by loss of interstitial cells of Cajal (ICC), and ultimately may affect the myenteric plexus ^[11]D5. This staging concept explains the progression from asymptomatic vascular deposits to clinically significant dysmotility. The presence of ICC loss or myenteric plexus involvement on full-thickness biopsy (when available) indicates advanced disease and predicts poor response to prokinetic therapy.

Localized vs Systemic Disease

Localized GI amyloidosis, most often presenting as a protruding lesion, carries an excellent prognosis. Malone et al. reported a 100% curative rate with surgical resection alone in localized cases ^[1]B2a. In contrast, systemic amyloidosis, especially with cardiac involvement, has a guarded prognosis. The endoscopic classification can help distinguish localized (protruding type) from systemic disease, guiding the need for further systemic workup.

Pearl: The protruding endoscopic type in GIA is a strong marker of localized disease and excellent prognosis, whereas hemorrhagic and ulcerative types should raise suspicion for systemic AL or AA amyloidosis, respectively, and prompt urgent cardiac and hematologic evaluation.

Once severity and risk are stratified, acute management focuses on the time-critical complications that bring patients to the hospital: gastrointestinal bleeding, obstruction, perforation, and severe malnutrition. The evidence base is limited to case series and expert opinion, so decisions must be individualized based on amyloid type, organ involvement, and the patient's overall condition.

Step 1: Initial Assessment and Resuscitation

For acute GI bleeding, initiate standard resuscitation with intravenous access, fluid resuscitation, and transfusion to a hemoglobin target of 7-8 g/dL. Obtain a complete blood count , coagulation profile, and type and screen. In patients with known or suspected cardiac amyloidosis , avoid aggressive fluid boluses that may precipitate heart failure. For suspected obstruction, place a nasogastric tube for decompression and obtain plain abdominal radiographs or CT to confirm the level and cause. Perforation requires immediate surgical consultation and broad-spectrum antibiotics .

Step 2: Endoscopic Intervention for Bleeding

Endoscopy is the first-line modality for diagnosis and treatment of GI bleeding in amyloidosis. However, the mucosa is often friable and the submucosal vessels are infiltrated by amyloid, making hemostasis challenging. The endoscopic classification proposed by Song et al. identifies five lesion types: protruding, granular, hemorrhagic, ulcerative, and nonspecific ^[7]D5. The hemorrhagic type is most common in AL amyloidosis (42.6% of AL cases) and carries a higher risk of bleeding ^[7]D5. In a series of 127 patients, the hemorrhagic type was the most frequent overall (25.2%) ^[7]D5. Endoscopic hemostatic techniques (injection, cautery, clips) may be attempted, but the risk of perforation is elevated because amyloid deposits weaken the bowel wall. If endoscopic control fails, proceed to angiography with embolization or surgical resection.

Step 3: Surgical Intervention for Obstruction and Perforation

Surgery is indicated for complete obstruction, perforation, or uncontrolled bleeding. In localized GI amyloidosis, resection alone achieves a 100% curative rate ^[1]B2a. In a systematic review of 62 patients with localized GI amyloidosis, all patients treated with surgical resection had complete response ^[1]B2a. For systemic amyloidosis, surgery carries high perioperative risk due to cardiac involvement (present in 83.5% of AL and 100% of ATTR patients) ^[9]D5. Preoperative echocardiography and cardiology consultation are mandatory. In one case, resection of a proliferating pilomatricoma with AA amyloid deposition led to resolution of GI symptoms and negative follow-up biopsies ^[6]C4. This suggests that removal of the source of amyloid precursor can reverse GI involvement.

Step 4: Medical Management of Underlying Amyloidosis

Acute management of GI symptoms must be paired with treatment of the underlying amyloid type. For AL amyloidosis, chemotherapy targeting the plasma cell clone is the mainstay. In a patient with multiple myeloma and secondary GI amyloidosis, 9 cycles of chemotherapy led to complete response of both myeloma and amyloidosis ^[14]C4. For AA amyloidosis, control of the underlying inflammatory condition is essential. In a mouse model of dermatitis-associated AA amyloidosis, Janus kinase (JAK) inhibitors improved GI amyloid deposition and hypoalbuminemia ^[10]D5. In a case of GI AA amyloidosis following SARS-CoV-2 infection, conservative management and remdesivir led to clinical and endoscopic improvement ^[13]C4. For localized AL amyloidosis without systemic involvement, conservative observation with regular surveillance may be reasonable, as demonstrated by a case that remained stable over 5 years ^[12]C4.

Step 5: Monitoring and Transition to Definitive Management

After acute stabilization, transition to long-term management as outlined in the next section. Monitor for recurrent bleeding, obstruction, or malnutrition. Serial clinical evaluations are recommended; in a systematic review, 62% of patients pursued serial clinical evaluations alone after treatment ^[1]B2a. For patients with elevated lesions (protruding type), prognosis is better: only 2 of 30 patients died during a median follow-up of 95.5 months, compared to 36.1% mortality for other endoscopic types ^[7]D5.

Table: Acute Management Options by Complication

What NOT to Do

• Do not perform endoscopic mucosal resection or submucosal dissection for protruding lesions, as the risk of perforation is high due to deep amyloid infiltration.
• Do not delay chemotherapy for AL amyloidosis while managing GI symptoms; systemic treatment is essential to halt progression.
• Do not assume that GI amyloidosis is always systemic; localized forms exist and may be managed conservatively ^[12]C4.

Pearl: In acute GI bleeding from amyloidosis, endoscopic hemostasis is first-line but carries a high perforation risk; surgical resection is curative for localized disease and should be considered early when endoscopic control fails ^[1]B2a[7]D5.

Once acute symptoms are controlled and the amyloid type is confirmed by proteomics or immunohistochemistry, long-term management diverges sharply by subtype. The treatment goal is to eliminate the amyloidogenic precursor protein, either by removing the local source, suppressing the plasma cell clone, or controlling the underlying inflammatory driver.

Step 1: Confirm Amyloid Type and Disease Extent

Typing by mass spectrometry-based proteomics is the gold standard; in a cohort of 2511 GI amyloid specimens, 12 different types were identified, and treatment hinges on correct classification ^[9]D5. Concurrently, determine whether disease is localized to the GI tract or part of systemic involvement. Cardiac involvement is found in 83.5% of AL and 100% of ATTR patients at diagnosis ^[9]D5, mandating echocardiography and cardiac biomarkers.

Step 2: Localized Gastrointestinal Amyloidosis

For truly localized disease, confirmed by absence of systemic organ involvement and negative hematologic workup, surgical resection is curative. In a systematic review of 62 patients, resection alone achieved a 100% cure rate ^[1]B2a. Among patients treated with systemic therapy for unresectable amyloidomas, 80% achieved a complete response ^[1]B2a. In carefully selected patients, conservative observation with regular surveillance may be reasonable: a case of localized AL-type GI amyloidosis remained endoscopically and clinically stable over 5 years without intervention ^[12]C4.

Step 3: Systemic AL Amyloidosis

Systemic AL amyloidosis is managed with chemotherapy targeting the underlying plasma cell clone ^[4]C4. Daratumumab -based regimens are first-line; the combination daratumumab, bortezomib, and dexamethasone (DVd) has been used successfully ^[5]C4. Cyclophosphamide is also employed ^[4]C4. The goal is hematologic complete response, which can lead to organ improvement. In one case, a patient with multiple myeloma and secondary GI amyloidosis achieved complete response of both myeloma and amyloidosis after 9 cycles of chemotherapy ^[14]C4. Cardiac involvement is common (83.5%) ^[9]D5; coordinate care with cardiology for heart failure management and arrhythmia monitoring.

Step 4: Systemic AA Amyloidosis

AA amyloidosis results from chronic inflammation; treatment focuses on controlling the underlying inflammatory condition to reduce serum amyloid A levels ^[4]C4. The specific approach depends on the cause:

• Tumor-associated AA: Resection of the inciting tumor can lead to remission of GI amyloidosis. A case of proliferating pilomatricoma with AA deposition showed resolution of diarrhea and negative colorectal biopsy after tumor excision ^[6]C4.
• Infection-associated AA: Treat the infection. In a case of GI AA amyloidosis following recurrent SARS-CoV-2 infection, conservative management plus remdesivir led to clinical and endoscopic improvement ^[13]C4.
• CVID-associated AA: Immunoglobulin replacement therapy and infection prophylaxis are mainstays ^[4]C4.
• Dermatitis-associated AA: In a mouse model, Janus kinase (JAK) inhibitors improved GI amyloidosis along with skin symptoms ^[10]D5.

Step 5: ATTR Amyloidosis

ATTR accounts for 11.3% of GI amyloid ^[9]D5. Cardiac involvement is universal in the proteomics cohort ^[9]D5. Management typically involves TTR stabilizers (tafamidis) or gene silencers (patisiran, vutrisiran), but specific GI-directed therapy is not reported in the provided evidence. Referral to a cardiomyopathy specialist is essential.

Step 6: Monitoring and Surveillance

• Localized disease: Serial clinical evaluations are recommended ^[1]B2a; endoscopic surveillance may be considered every 1-2 years ^[12]C4.
• Systemic disease: Monitor hematologic response (serum free light chains, immunofixation) and organ function (cardiac biomarkers, renal function, albumin). Repeat endoscopy with biopsy if symptoms recur.

What NOT to Do

• Do not assume all GI amyloid is AL; over 10% are ATTR and over 5% are AA ^[9]D5. Typing is mandatory before initiating therapy.
• Do not perform surgical resection for systemic disease without addressing the underlying clone or inflammation, it will not halt progression.
• Do not use corticosteroids alone for AA amyloidosis without treating the primary inflammatory driver; they may provide transient symptomatic benefit but do not eliminate the amyloid precursor ^[4]C4.

Pearl: Long-term management of GI amyloidosis hinges on accurate amyloid typing; localized disease is curable with resection, while systemic AL requires clone-directed chemotherapy and AA requires control of the underlying inflammatory driver.

For localized gastrointestinal amyloidosis, endoscopic or surgical resection achieves a 100% curative rate ^[1]B2a. This section outlines the procedural approach, from endoscopic classification to resection and surveillance, that runs in parallel with medical therapy for systemic disease.

Step 1: Endoscopic Classification and Risk Stratification

Endoscopic findings in GIA are diverse but classifiable into five types with distinct prognostic implications ^[7]D5. The protruding type (23.6% of cases) is significantly associated with localized amyloidosis (71.4% of protruding lesions) and carries a favorable prognosis: only 2 of 30 patients died during a median follow-up of 95.5 months, compared with 36.1% mortality for the other types combined (p=0.007) ^[7]D5. The hemorrhagic type (25.2%) predominates in AL amyloidosis (42.6%), while the ulcerative type (22.0%) is most common in AA amyloidosis (47.1%) ^[7]D5. The granular type (15.7%) correlates with dysmotility symptoms (p=0.018), and the nonspecific type (13.4%) carries no distinctive association ^[7]D5. This classification guides both diagnostic suspicion and management strategy.

Step 2: Biopsy Technique for Diagnostic Yield

Histopathological confirmation requires deep tissue sampling. The small intestine has the highest detection rate (100%), while the colorectum has the lowest (37.5%) ^[3]B3b. Targeted biopsies should include the submucosa, as amyloid deposits often involve deeper layers; the mucosal layer is predominantly affected in the esophagus and stomach, whereas the submucosa is more involved in the duodenum and colon ^[3]B3b. Congo red staining with apple-green birefringence under polarized light remains the gold standard ^[8]D5. For patients with unexplained gastric erythema, narrow-band imaging (NBI) may reveal a grayish-green signal with a layered, deeper-appearing distribution that helps differentiate amyloidosis from other causes of erythema ^[5]C4.

Step 3: Resection for Localized Disease

Localized GI amyloidosis, most often presenting as a protruding lesion, is curable with complete resection. In a systematic review of 62 patients, resection alone achieved a 100% curative rate ^[1]B2a. Endoscopic resection (polypectomy, endoscopic mucosal resection) is appropriate for accessible lesions; surgical resection is reserved for larger or deeper amyloidomas. For patients with non-resectable localized disease, systemic therapy (e.g., chemotherapy for AL type) produced an 80% complete response rate ^[1]B2a.

Step 4: Surveillance After Resection

After curative resection, surveillance should include serial clinical evaluations (62% of reported cases) ^[1]B2a. For localized AL-type amyloidosis, conservative observation without further intervention may be reasonable after excluding systemic involvement; one case remained endoscopically and clinically stable over 5 years ^[12]C4. Routine follow-up endoscopy is not mandated but should be considered if new GI symptoms arise.

Step 5: Endoscopic Management of Systemic Disease Complications

In systemic amyloidosis, endoscopic procedures are primarily diagnostic but may manage complications. For GI bleeding from hemorrhagic or ulcerative lesions, endoscopic hemostasis (injection, coagulation, clips) can be applied, though data are limited to case reports ^[13]C4. For obstructive symptoms from large amyloidomas, endoscopic dilation or stent placement may provide palliation. Perforation is a rare but serious complication requiring surgical repair ^[8]D5.

Step 6: Surgical Resection for Refractory Cases

Surgical resection is indicated for complications such as perforation, obstruction, or bleeding not amenable to endoscopic therapy. In one case, resection of a proliferating pilomatricoma with AA amyloid deposition led to remission of concomitant GI amyloidosis, with resolution of diarrhea and negative follow-up biopsies ^[6]C4. This highlights that removal of the amyloidogenic source can reverse GI involvement.

Table: Endoscopic Classification of Gastrointestinal Amyloidosis and Management Implications

Controversies and Guideline Disagreement

No major guideline disagreements were identified for this topic in the reviewed evidence. The management of localized GI amyloidosis is based on case series and expert opinion, with no prospective trials comparing resection versus observation. The 100% curative rate with resection alone ^[1]B2a supports an aggressive approach for localized disease, but the option of conservative observation for selected patients ^[12]C4 remains a point of clinical judgment.

Pearl: Endoscopic classification into protruding, hemorrhagic, ulcerative, granular, or nonspecific types stratifies prognosis and guides management, protruding lesions are typically localized and curable with resection, while hemorrhagic and ulcerative types signal systemic disease requiring coordinated medical therapy ^[1]B2a[7]D5.

Following endoscopic management of bleeding or obstructive lesions, the therapeutic approach to gastrointestinal amyloidosis has evolved substantially over the past three decades, driven by improved understanding of amyloid typing and the development of disease-modifying therapies. Early management was purely symptomatic, supportive care for diarrhea, nutritional support, and blood transfusions, because the underlying disease was poorly understood and no effective disease-modifying agents existed. The recognition that amyloid deposits are composed of specific precursor proteins (light chains in AL, serum amyloid A in AA, transthyretin in ATTR) shifted the paradigm: treatment must target the source of the precursor, not the organ deposits themselves.

Early Era: Symptomatic Management

Before the 1990s, therapy for gastrointestinal amyloidosis was limited to addressing complications. Patients with rheumatoid arthritis -associated AA amyloidosis were managed with anti-inflammatory drugs, but outcomes were poor. A landmark case from 2003 demonstrated that aggressive immunosuppression could reverse AA gastrointestinal amyloidosis: a 35-year-old woman with active RA of only 1 year developed intractable watery diarrhea due to secondary intestinal amyloidosis. Combination treatment with intravenous hyperalimentation, corticosteroids, and methotrexate (MTX) resulted in a dramatic improvement of her symptoms and objective findings of serological abnormalities ^[21]C4. This case highlighted that controlling the underlying inflammatory disease could halt and even reverse AA amyloid deposition, establishing the principle of precursor-directed therapy.

Emergence of Amyloid-Targeted Therapy

The pivotal advance came with the application of high-dose chemotherapy followed by autologous stem-cell transplantation (ASCT) for AL amyloidosis. A 2008 review of gastrointestinal amyloidosis noted that "disease modifying treatment with high-dose chemotherapy followed by autologous stem-cell transplantation has shown promise" ^[2]D5. This approach, borrowed from multiple myeloma , aimed to eradicate the clonal plasma cells producing amyloidogenic light chains. Subsequent experience confirmed that ASCT became the standard of care for AL amyloidosis with plasma cell dyscrasia ^[13]C4. For patients with ATTR amyloidosis, liver transplantation emerged as an option because the liver produces the majority of mutant transthyretin; the same review stated that "liver transplantation is an option for a select group of patients" ^[2]D5.

Current Standards by Amyloid Type

The evolution from symptomatic care to type-specific, disease-modifying therapy has transformed outcomes. For AL amyloidosis, the median survival historically was measured in months; with ASCT, durable remissions are achievable. For AA amyloidosis, aggressive control of the underlying inflammatory condition, whether rheumatoid arthritis, inflammatory bowel disease, or chronic infection, can lead to regression of gastrointestinal deposits and symptom resolution. The key lesson from this therapeutic timeline is that amyloid typing is not merely diagnostic, it dictates the treatment strategy.

Pearl: The single most important advance in gastrointestinal amyloidosis treatment was the recognition that therapy must be directed at the specific amyloid precursor protein, not the organ involvement; typing the amyloid before initiating therapy is mandatory.

Despite advances in therapy, patients with gastrointestinal amyloidosis remain at risk for a spectrum of local and systemic complications that require vigilant surveillance and proactive management. The most common complication is gastrointestinal bleeding, occurring in 36% of patients with biopsy-proven disease ^[17]B2b. Severe hemorrhage, defined as requiring transfusion, operative intervention, or interventional radiology, occurred in 6% of patients treated with high-dose melphalan and autologous stem cell transplantation (HDM/SCT) ^[17]B2b. Recurrent bleeding from multiple small intestinal sites may necessitate repeated embolization; one reported case required eight embolization procedures before bleeding ceased ^[19]C4. Prevention hinges on careful patient selection: those with active GI bleeding or ulceration should not receive myeloablative chemotherapy because of the risk of catastrophic hemorrhage ^[17]B2b. Management includes supportive care, endoscopic hemostasis, interventional radiology, and, rarely, surgery.

Gastric Outlet Obstruction

Amyloid deposition can cause gastric wall thickening that mimics linitis plastica, leading to gastric outlet obstruction (GOO) ^[23]C4. In a patient with smoldering myeloma and GOO, a non-operative approach with chemotherapy produced a good clinical response, avoiding perioperative risks and allowing early initiation of systemic therapy ^[22]C4. Surgery is reserved for refractory cases; one patient who refused operation died of aspiration pneumonia three months later ^[23]C4.

Bowel Perforation

Perforation is a rare but life-threatening complication. In a patient with secondary amyloidosis due to rheumatoid arthritis, small intestinal perforation occurred two days after administration of tocilizumab for life-threatening diarrhea ^[24]C4. Whether tocilizumab contributed directly is unknown, but the event underscores the fragility of amyloid-infiltrated bowel. Surgical repair is the mainstay of management.

Motility Disorders and Malabsorption

Amyloid deposits in smooth muscle and neural plexuses disrupt motility, causing gastroparesis , pseudo-obstruction, diarrhea, and malabsorption ^[8]D5. These symptoms are often multifactorial, arising from autonomic neuropathy , bacterial overgrowth, or direct infiltration ^[2]D5. Supportive care includes prokinetics (e.g., metoclopramide, erythromycin), antiemetics (ondansetron, granisetron, prochlorperazine), and antidiarrheals (loperamide, lomotil, deodorized tincture of opium) ^[17]B2b.

Treatment-Related Toxicities

Among 16 evaluable patients receiving first-line therapy for systemic AL amyloidosis, the most frequent regimen-related toxicities (NCI CTCAE v3.0 grade 1-4) were diarrhea (56%), nausea (50%), constipation (62%), GI bleeding (25%), and anorexia (44%) ^[17]B2b. One patient (6%) experienced life-threatening dehydration; no other life-threatening GI toxicities were documented ^[17]B2b. Dose modification and aggressive supportive care are essential.

Autonomic Dysfunction

Autonomic neuropathy contributes to GI symptoms and complications such as orthostatic hypotension, arrhythmias, ileus, and urinary retention ^[2]D5. In ATTR amyloidosis, autonomic dysfunction plays a major role in disease progression and may complicate liver transplantation ^[17]B2b. Management includes volume repletion, antiarrhythmics, and bowel/bladder regimens.

Pearl: Severe GI hemorrhage complicates only 6% of HDM/SCT cases in carefully selected patients, but recurrent bleeding from multiple sites may require repeated embolization, always assess bleeding risk before initiating myeloablative therapy.

The complications of gastrointestinal amyloidosis, bleeding, perforation, malnutrition, underscore the importance of understanding its trajectory, which diverges sharply by amyloid type and extent of disease. Localized GI amyloidosis carries an excellent prognosis: in a systematic review of 62 patients, curative resection achieved a 100% cure rate ^[1]B2a. Among patients treated with systemic therapy for non-resectable disease, 80% attained a complete response ^[1]B2a. A case of localized AL-type GI amyloidosis remained endoscopically and clinically stable over 5 years of surveillance, supporting conservative observation after excluding systemic involvement ^[12]C4.

Natural History and Disease Progression

Systemic amyloidosis follows a progressive course if untreated. In AL amyloidosis, early mortality remains high, nearly 20% of patients die within 6 months of diagnosis, a statistic unchanged over four decades ^[4]C4. Pulmonary amyloidosis, most often AL type, carries a median survival of 16 months ^[4]C4. Cardiac involvement is frequent: 83.5% of AL and 100% of ATTR patients ultimately have cardiac amyloid ^[9]D5. GI amyloidosis is usually an unexpected finding that signals systemic disease; in one proteomics-based series of 2511 GI specimens, AL accounted for 77.9%, ATTR 11.3%, and AA 6.6% ^[9]D5.

Intestinal dysmotility in amyloidosis follows a sequential histologic process: amyloid deposition begins in the vasculature, then involves the muscular layers, leads to loss of interstitial cells of Cajal, and eventually affects the myenteric plexus, a final stage accompanied by severe dysmotility symptoms ^[11]D5.

Prognostic Factors

Endoscopic classification predicts survival. In a study of 127 patients, five endoscopic types were identified: protruding, granular, hemorrhagic, ulcerative, and nonspecific. The protruding type was associated with significantly better survival, only 2 of 30 patients died versus 36.1% of patients with other types during a median follow-up of 95.5 months (p=0.007) ^[7]D5. The protruding type was most common in localized amyloidosis (71.4%), while the hemorrhagic type predominated in AL (42.6%) and the ulcerative type in AA (47.1%) ^[7]D5.

Amyloid type itself is a major determinant. AA amyloidosis secondary to chronic inflammation may remit if the underlying condition is controlled: resection of a pilomatricoma with AA deposition led to resolution of GI symptoms and negative follow-up biopsies ^[6]C4. Similarly, GI AA amyloidosis after SARS-CoV-2 infection improved with conservative management ^[13]C4. In multiple myeloma -associated GI amyloidosis, complete response of both myeloma and amyloidosis was achieved after 9 cycles of chemotherapy ^[14]C4.

Outcomes by Amyloid Type

Long-term Surveillance

After treatment, surveillance is inconsistently reported. In the systematic review, only 62% of patients underwent serial clinical evaluations post-treatment ^[1]B2a. For localized disease, endoscopic follow-up may be reasonable; for systemic disease, monitoring should include assessment of cardiac, renal, and hematologic parameters.

Pearl: The single strongest predictor of favorable outcome in GI amyloidosis is the presence of localized disease amenable to resection, curative in 100% of reported cases, whereas systemic AL amyloidosis carries a 20% early mortality within 6 months, mandating urgent hematologic referral.

The median age at diagnosis of gastrointestinal amyloidosis is 61 to 64 years, with patients ranging from 34 to 79 years ^{[1]B2a[17]B2b[18]C4}. This age distribution shapes management considerations, particularly in the elderly, while data for other special populations remain sparse.

Elderly

Elderly patients with gastrointestinal amyloidosis frequently carry comorbid organ involvement that alters the risk-benefit balance of therapy. In the largest reported series of 76 patients with biopsy-proven GI amyloidosis, systemic AL disease was accompanied by cardiac involvement in 48%, renal involvement in 36%, and neurologic involvement in 38% ^[17]B2b. These comorbidities increase the vulnerability to treatment-related toxicity. High-dose melphalan with autologous stem cell transplantation (HDM/SCT) was offered as first-line therapy to selected patients, but those with active GI bleeding or ulceration were excluded because of the risk of catastrophic GI hemorrhage ^[17]B2b. Among 16 evaluable patients, severe GI hemorrhage requiring transfusion or intervention occurred in only 6%, and no deaths from GI bleeding were reported ^[17]B2b. For elderly patients with localized GI amyloidosis, supportive care without systemic therapy is the mainstay; all 16 patients with localized disease in that series were alive at a median follow-up of 36 months ^[17]B2b. The 2- and 4-year survival rates for systemic AL with GI involvement were 84% and 72%, respectively ^[17]B2b.

Pediatrics

The available literature does not report specific cases or outcomes of gastrointestinal amyloidosis in pediatric populations. Given the rarity of systemic amyloidosis in children, diagnosis is often delayed. When suspected, biopsy with Congo red staining and amyloid typing by mass spectrometry should follow the same principles as in adults, but no age-adjusted treatment protocols have been validated.

Pregnancy

No data on gastrointestinal amyloidosis during pregnancy are available from the reviewed evidence. Management requires a multidisciplinary approach involving hematology, gastroenterology, and maternal-fetal medicine. Chemotherapeutic agents commonly used for AL amyloidosis, such as melphalan, lenalidomide, and thalidomide, are teratogenic and should be avoided during pregnancy. Supportive care and delivery planning should prioritize maternal stability while minimizing fetal exposure.

Immunocompromised

Patients with underlying plasma cell dyscrasias, including multiple myeloma , are at risk for AL amyloidosis with GI involvement ^{[15]C4[17]B2b}. In the series by Cowan et al., 14% of systemic AL patients had coexistent multiple myeloma ^[17]B2b. Chemotherapy regimens included bortezomib, melphalan, dexamethasone , lenalidomide, and thalidomide ^[17]B2b. In patients with active GI bleeding or ulceration, myeloablative chemotherapy is contraindicated because of the risk of catastrophic hemorrhage ^[17]B2b. Supportive care with antiemetics (ondansetron, granisetron, prochlorperazine) and antidiarrheals (loperamide, lomotil, deodorized tincture of opium) is recommended for symptom control ^[17]B2b.

Pearl: In elderly patients with GI amyloidosis, the presence of active GI bleeding or ulceration is a contraindication to myeloablative chemotherapy; supportive care alone achieves excellent survival in localized disease, with 100% alive at a median 36 months ^[17]B2b.

For patients who survive the acute phase, the focus shifts to preventing disease progression and detecting recurrence. Prevention strategies for gastrointestinal amyloidosis are anchored to the underlying amyloid type and its driving condition.

Primary Prevention

Controlling the chronic inflammatory or neoplastic stimulus that drives amyloid fibril production is the cornerstone of primary prevention. In AA amyloidosis, aggressive treatment of the underlying inflammatory disease, whether rheumatoid arthritis, familial Mediterranean fever, or chronic infection, reduces serum amyloid A levels and halts new amyloid deposition. Resection of a solid tumor containing AA amyloid deposits has been reported to reverse concomitant gastrointestinal AA amyloidosis, with resolution of diarrhea and clearance of amyloid on follow-up biopsy ^[6]C4. In a mouse model of chronic dermatitis, Janus kinase inhibitors improved gastrointestinal amyloidosis alongside skin symptoms, suggesting that tight control of inflammation prevents secondary gastrointestinal involvement ^[10]D5. For AL amyloidosis, primary prevention targets the plasma cell clone; no specific gastrointestinal prophylaxis exists beyond standard anti-clone therapy.

Secondary Prevention and Surveillance

After successful treatment of gastrointestinal amyloidosis, surveillance aims to detect recurrence or progression. In localized gastrointestinal amyloidosis, where curative resection achieves a 100% response rate, serial clinical evaluations alone were used in 62% of reported cases ^[1]B2a. For patients with localized AL-type amyloidosis who are managed conservatively, regular endoscopic surveillance is reasonable: one case remained endoscopically and clinically stable over 5 years without intervention ^[12]C4. In systemic amyloidosis, surveillance should include periodic clinical assessment for gastrointestinal symptoms and, when indicated, repeat endoscopy with biopsy. The optimal interval is not established by prospective data, but annual clinical evaluation is a pragmatic minimum.

Screening Recommendations

Screening for gastrointestinal amyloidosis is not population-based but is indicated in high-risk groups. Patients with systemic amyloidosis, particularly AL and ATTR types, should undergo upper endoscopy with biopsy if they develop unexplained gastrointestinal symptoms such as diarrhea, abdominal pain, weight loss, or bleeding. The evidence supports a low threshold: gastrointestinal amyloid is often an unexpected finding, but most patients with AL or ATTR amyloidosis ultimately have cardiac involvement, and a positive gastrointestinal biopsy can confirm systemic disease ^[9]D5. In patients with common variable immunodeficiency (CVID), who are at risk for AA amyloidosis due to recurrent infections and immune dysregulation, clinicians should maintain a high index of suspicion and consider endoscopic biopsy when gastrointestinal symptoms arise ^[4]C4. The diagnostic yield is highest in the small intestine (100% in one series) and duodenum (88.9%), and lowest in the colorectum (37.5%) ^[3]B3b.

Vaccine Considerations

Patients with CVID and other immunodeficiencies who develop gastrointestinal amyloidosis require careful vaccine management. Inactivated vaccines (e.g., influenza, pneumococcal, SARS-CoV-2) are recommended to reduce infection-related inflammation that could drive AA amyloid deposition ^[4]C4. Live attenuated vaccines are contraindicated in these patients due to the risk of disseminated infection. For patients on immunosuppressive therapy for AL amyloidosis, vaccination should follow standard guidelines for immunocompromised hosts.

Patient Education

Patients should be counseled that gastrointestinal amyloidosis is a marker of systemic disease in most cases and that adherence to treatment of the underlying condition is essential. They should report new or worsening gastrointestinal symptoms promptly. For those with localized disease, education about the excellent prognosis after resection and the importance of follow-up can reduce anxiety and improve compliance.

Pearl: In any patient with systemic amyloidosis who develops new gastrointestinal symptoms, endoscopic biopsy with Congo red staining should be performed without delay, the small intestine and duodenum offer the highest diagnostic yield, and a positive result confirms systemic involvement ^[3]B3b[9]D5.